Found: 45
Select item for more details and to access through your institution.
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 10, p. 7565, doi. 10.1007/s00432-023-04678-2
- By:
- Publication type:
- Article
Immunotherapy in Gastrointestinal Cancers.
- Published in:
- BioMed Research International, 2017, v. 2017, p. 1, doi. 10.1155/2017/4346576
- By:
- Publication type:
- Article
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
- Published in:
- 2018
- By:
- Publication type:
- journal article
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study.
- Published in:
- Clinical & Experimental Medicine, 2024, v. 24, n. 1, p. 1, doi. 10.1007/s10238-023-01263-2
- By:
- Publication type:
- Article
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-25558-8
- By:
- Publication type:
- Article
Prospective Validation of Candidate SNPs of <i>VEGF/VEGFR</i> Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab.
- Published in:
- PLoS ONE, 2013, v. 8, n. 7, p. 1, doi. 10.1371/journal.pone.0066774
- By:
- Publication type:
- Article
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3217, doi. 10.1007/s00262-023-03489-1
- By:
- Publication type:
- Article
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.
- Published in:
- Cancers, 2023, v. 15, n. 24, p. 5758, doi. 10.3390/cancers15245758
- By:
- Publication type:
- Article
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study.
- Published in:
- Cancers, 2023, v. 15, n. 14, p. 3625, doi. 10.3390/cancers15143625
- By:
- Publication type:
- Article
Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS G12C -Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis.
- Published in:
- Cancers, 2023, v. 15, n. 11, p. 3064, doi. 10.3390/cancers15113064
- By:
- Publication type:
- Article
Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial.
- Published in:
- Cancers, 2020, v. 12, n. 7, p. 1742, doi. 10.3390/cancers12071742
- By:
- Publication type:
- Article
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data.
- Published in:
- Liver International, 2023, v. 43, n. 8, p. 1803, doi. 10.1111/liv.15641
- By:
- Publication type:
- Article
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 2, p. 215, doi. 10.1159/000534127
- By:
- Publication type:
- Article
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
- Published in:
- PLoS ONE, 2020, v. 15, n. 9, p. 1, doi. 10.1371/journal.pone.0239439
- By:
- Publication type:
- Article
Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients.
- Published in:
- Cancer Genomics & Proteomics (1109-6535), 2021, v. 18, n. 3, p. 317, doi. 10.21873/cgp.20262
- By:
- Publication type:
- Article
CK7 and consensus molecular subtypes as major prognosticators in <sup>V600E</sup>BRAF mutated metastatic colorectal cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
- Published in:
- Clinical Colorectal Cancer, 2020, v. 19, n. 3, p. 219, doi. 10.1016/j.clcc.2020.04.009
- By:
- Publication type:
- Article
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis.
- Published in:
- Clinical Colorectal Cancer, 2020, v. 19, n. 3, p. 191, doi. 10.1016/j.clcc.2020.03.009
- By:
- Publication type:
- Article
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
- Published in:
- 2018
- By:
- Publication type:
- journal article
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00622
- By:
- Publication type:
- Article
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
- Published in:
- International Journal of Cancer, 2020, v. 147, n. 8, p. 2303, doi. 10.1002/ijc.33003
- By:
- Publication type:
- Article
Genetic variants in CCL5 and CCR5 genes and serum VEGF‐A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
- Published in:
- International Journal of Cancer, 2019, v. 144, n. 10, p. 2567, doi. 10.1002/ijc.31968
- By:
- Publication type:
- Article
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
- Published in:
- International Journal of Cancer, 2017, v. 141, n. 6, p. 1222, doi. 10.1002/ijc.30810
- By:
- Publication type:
- Article
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
- Published in:
- International Journal of Cancer, 2017, v. 141, n. 2, p. 383, doi. 10.1002/ijc.30715
- By:
- Publication type:
- Article
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
- Published in:
- International Journal of Cancer, 2015, v. 136, n. 1, p. 83, doi. 10.1002/ijc.28955
- By:
- Publication type:
- Article
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 3, p. 371, doi. 10.1007/s11523-024-01050-3
- By:
- Publication type:
- Article
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 3, p. 359, doi. 10.1007/s11523-024-01060-1
- By:
- Publication type:
- Article
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 2, p. 223, doi. 10.1007/s11523-024-01032-5
- By:
- Publication type:
- Article
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 4, p. 517, doi. 10.1007/s11523-021-00816-3
- By:
- Publication type:
- Article
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 3, p. 205, doi. 10.1007/s11523-013-0284-7
- By:
- Publication type:
- Article
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 6, p. 1523, doi. 10.1002/cncr.26460
- By:
- Publication type:
- Article
Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?
- Published in:
- Oncologist, 2019, v. 24, n. 2, p. e77, doi. 10.1634/theoncologist.2018-0180
- By:
- Publication type:
- Article
Safety and Tolerability of c-MET Inhibitors in Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.
- Published in:
- PLoS ONE, 2018, v. 13, n. 3, p. 1, doi. 10.1371/journal.pone.0193640
- By:
- Publication type:
- Article
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
- Published in:
- Current Oncology, 2023, v. 30, n. 6, p. 5456, doi. 10.3390/curroncol30060413
- By:
- Publication type:
- Article
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
- Published in:
- Current Oncology, 2023, v. 30, n. 5, p. 5103, doi. 10.3390/curroncol30050386
- By:
- Publication type:
- Article
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer.
- Published in:
- Cancer Cell International, 2020, v. 20, n. 1, p. 1, doi. 10.1186/s12935-020-1117-2
- By:
- Publication type:
- Article
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
- Published in:
- BMC Cancer, 2011, v. 11, n. 1, p. 247, doi. 10.1186/1471-2407-11-247
- By:
- Publication type:
- Article